What is the 13F Pro Quality Score for JNJ?

13F Pro ranks JOHNSON & JOHNSON (JNJ) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View JNJ's current score at https://13fpro.ai/research/JNJ (free sign-up required for the full ranking).

Which hedge funds own the most JNJ stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of JNJ include BlackRock,, VANGUARD CAPITAL MANAGEMENT, STATE STREET. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/JNJ as soon as new 13F filings post.

Where does 13F Pro source JNJ data?

All JOHNSON & JOHNSON fundamentals and ownership data come directly from SEC EDGAR. JOHNSON & JOHNSON files with the SEC under CIK 200406. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is JNJ in?

JOHNSON & JOHNSON (JNJ) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is JNJ research updated on 13F Pro?

JNJ's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

JOHNSON & JOHNSON(JNJ)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 200406 JNJ stock profile & AI dashboard →

13F Pro Quality Score

72.8/100

Rank #214 of 2,879 stocksTOP 10%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

50.6/100

Profitability

86.5/100

Balance Sheet

91.7/100

Earnings Quality

25.4/100

Free Cash Flow

74.9/100

Institutional Flow

37.9/100

Revenue Scale

98.8/100

Dilution Risk

48.2/100

JNJ Stock Analysis & AI Quality Score

AI stock analysis and institutional research for JOHNSON & JOHNSON (JNJ), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores JNJ at 72.8/100 on a 32-signal composite quality model, placing it at rank #214 of 2,879 stocks — the top 10% of the AI-ranked universe. JNJ scores in the top quartile across revenue scale (98.8), balance sheet strength (91.7), profitability (86.5). Areas of concern include earnings quality (25.4) and institutional flow (37.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 48.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), JOHNSON & JOHNSON reports quarterly revenue of $24.1B, net income of $5.2B, an operating margin of 24.9%. Top institutional holders of JNJ by reported 13-F value include BlackRock,, VANGUARD CAPITAL MANAGEMENT, STATE STREET, based on the most recent SEC filings. JNJ trades on the NYSE exchange and files with the SEC under CIK 200406. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate JNJ daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for JOHNSON & JOHNSON directly from SEC EDGAR. JOHNSON & JOHNSON's 13F Pro composite quality score has ranged between 46 and 77 since 2021, currently 72.8 — a stable long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about JOHNSON & JOHNSON

Quirks, history, and lore behind JNJ — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. healthcare company · mega-cap · listed on the NYSE · headquartered in New Jersey.
2
The Numbers
Revenue of roughly $85 billion a year spread across pharmaceuticals and medical devices — one of the most diversified healthcare giants on the planet.
3
The History
Founded in 1886 by three brothers, it became a household name by making sterile surgical supplies at a time when most doctors still thought germs were optional.
4
The Secret
In 1982, a product-tampering crisis killed seven people and nearly destroyed one of its biggest brands — its swift recall became a gold standard for corporate crisis management.
5
The Lore
It recently spun off its consumer products division — including that famous no-more-tears baby shampoo — to focus purely on pharmaceuticals and medical devices.
6
The Giveaway
A red cross on a bandage, a bottle of baby powder with decades of litigation attached, and a name so wholesome it's literally a family twice over.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$24.1B

Net Income

Q1 2026

$5.2B

Free Cash Flow

Q1 2026

$1.5B

Operating Margin

Q1 2026

24.9%

D/E Ratio

Q1 2026

0.68

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+6.0% YoY

$94.19BFY 2025

FY22 $79.99BFY23 $85.16BFY24 $88.82BFY25 $94.19B

Net Income

+90.6% YoY

$26.80BFY 2025

FY22 $17.94BFY23 $35.15BFY24 $14.07BFY25 $26.80B

EPS (Diluted)

+90.5% YoY

$11.03FY 2025

FY22 $6.73FY23 $13.72FY24 $5.79FY25 $11.03

Total Assets

+10.6% YoY

$199.21BFY 2025

FY22 $187.38BFY23 $167.56BFY24 $180.10BFY25 $199.21B

Total Debt

+31.0% YoY

$60.43BFY 2025

FY22 $55.54BFY23 $35.77BFY24 $46.13BFY25 $60.43B

Op. Cash Flow

+1.1% YoY

$24.53BFY 2025

FY22 $21.19BFY23 $22.79BFY24 $24.27BFY25 $24.53B

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$94.19B +6.0%	$88.82B +4.3%	$85.16B +6.5%	$79.99B +1.6%	$78.74B -4.7%	$82.58B
Net Income	$26.80B +90.6%	$14.07B -60.0%	$35.15B +95.9%	$17.94B -14.1%	$20.88B +41.9%	$14.71B
EPS (Diluted)	$11.03 +90.5%	$5.79 -57.8%	$13.72 +103.9%	$6.73 -13.8%	$7.81 +41.7%	$5.51
Total Assets	$199.21B +10.6%	$180.10B +7.5%	$167.56B -10.6%	$187.38B +2.9%	$182.02B +4.1%	$174.89B
Total Debt	$60.43B +31.0%	$46.13B +29.0%	$35.77B -35.6%	$55.54B +32.8%	$41.81B +0.8%	$41.46B
Operating Cash Flow	$24.53B +1.1%	$24.27B +6.5%	$22.79B +7.5%	$21.19B -9.5%	$23.41B -0.5%	$23.54B

AI Insight: JNJ Financial Trends

Revenue growth accelerating while operating cash flow deteriorates sharply in Q1 2026.

• Revenue grew 9.9% from Q2 2024 ($22.4B) to Q1 2026 ($24.1B), with Q4 2025 peak at $24.6B.

• Net income volatile: Q1 2025 spike to $11.0B followed by normalized ~$5.1–5.5B run rate Q2–Q1 2026.

• Operating cash flow collapsed to $2.5B in Q1 2026 from $9.2B in Q3 2025—lowest in dataset.

⚠ Total debt spiked to $60.4B in Q4 2025, up $14.6B in one quarter; now elevated vs. equity coverage.

⚠ Operating cash flow remains depressed at $2.5B Q1 2026; below $4.2B Q1 2025 and historical run rate.

Get alerted when JNJ's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for JOHNSON & JOHNSON including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of JNJ

BlackRock, Inc.
$52.2B213,385,546 sh
VANGUARD CAPITAL MANAGEMENT LLC
$38.3B156,605,370 sh
STATE STREET CORP
$32.6B133,476,288 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$15.5B63,514,436 sh
GEODE CAPITAL MANAGEMENT, LLC
$14.4B59,164,862 sh
MORGAN STANLEY
$10.9B44,721,167 sh
STATE FARM MUTUAL AUTOMOBILE INSURANCE CO
$7.7B31,590,952 sh
NORTHERN TRUST CORP
$7.2B29,319,669 sh
BANK OF AMERICA CORP /DE/
$6.2B25,516,697 sh
FMR LLC
$6.1B24,771,828 sh

Fund	Value	Shares
BlackRock, Inc.	$52.2B	213,385,546
VANGUARD CAPITAL MANAGEMENT LLC	$38.3B	156,605,370
STATE STREET CORP	$32.6B	133,476,288
VANGUARD PORTFOLIO MANAGEMENT LLC	$15.5B	63,514,436
GEODE CAPITAL MANAGEMENT, LLC	$14.4B	59,164,862
MORGAN STANLEY	$10.9B	44,721,167
STATE FARM MUTUAL AUTOMOBILE INSURANCE CO	$7.7B	31,590,952
NORTHERN TRUST CORP	$7.2B	29,319,669
BANK OF AMERICA CORP /DE/	$6.2B	25,516,697
FMR LLC	$6.1B	24,771,828

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put JNJ on your watchlist

Track score changes the day JOHNSON & JOHNSON files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is JNJ a good stock to buy?

13F Pro's AI-powered analysis of JOHNSON & JOHNSON (JNJ) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for JNJ are available on the JNJ stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own JNJ?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling JNJ. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of JOHNSON & JOHNSON's investment landscape.